FDA Slaps Aurobindo Pharma with Form 483

Apr 19, 2017

Business Standard

Aurobindo Pharma stocks dropped 4.7% on BSE after the company said the FDA issued six large procedural observations for its Unit III, a formulation manufacturing facility located at Bachupally, Hyderabad.

The Food and Drug Administration conducted an inspection at the company’s Unit III, a formulation manufacturing facility located at Bachupally, Hyderabad, from April 10-18, 2017, according to an article in Business Standard.

The company said the observations were all regarding procedural improvements, and none of those were related to data integrity.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments